

Contents

1	Introduction	1
	References and Notes	6
2	Uncovering the Interaction of Chemistry and Behavior in Depression: The Dimensional Versus Diagnostic Approaches in Structuring Research	9
	Neurotransmitter-Behavioral Relationships	11
	References and Notes	13
3	Depression is a “Storm” not a Lowering of Spirit: The Experience and Psychology of the Severe Depressive State	15
	The Impact of the Drugs on US and European Theoretical Orientations	16
	The Experiential State	17
	The Impact of the Drug Era	18
	References	19
4	“Rashomon” and the Componential Approach to Developing Measures of Mood and Behavior	21
	The “Multi-vantaged” Method: The “Rashomon” Approach	25
	Video Interview Behavioral Evaluation Study (VIBES) [15]	27
	Applying the Multi-vantage Behavioral Method to Studying the Nature of the Depressed State: The Components, Dimensions, and the Conflictual Nature of the State	29
	The Key Roles of Anxiety and Hostility in the Patient Profile	29
	References	32
5	Dimensions of Depression: The Conflictual Structure of the Depressed State	35
	A Multidimensional Theory of the Nature of Depression	36
	References	37

6	False Assumptions: The Multidimensional Quality and its Relationships to Functioning of the Central Nervous System	39
	Behavioral Correlates of Central Neurotransmitters	
	in the Affective Disorders [13–15]	40
	The Noradrenergic Systems and Behavior	41
	Serotonin and Behavior	42
	On Dopamine	43
	The Neurotransmitter Systems and Depression:	
	Relating Actions of the Noradrenergic	
	and Serotonergic Systems to Specific	
	Behavioral Changes in Depressed Patients	44
	The Therapeutic Process: The Sequence	
	and Nature of Tricyclic Drug Actions in Depression	46
	Linking Behavioral Changes with Drug-Induced Changes in	
	Neurotransmitter System Functioning: Relationships	
	of Changes in Cerebrospinal Fluid Concentrations	
	of Neurotransmitter Metabolites and Behavior	49
	References	50
7	Testing New Hypotheses About Neurochemistry, Depression, and Drugs	53
	On Pharmacologically Different Drugs	55
	References	59
8	Developing a More Effective and More Efficient Clinical Trial Model	61
	The Current Food and Drug Administration (FDA) Endorsed	
	Clinical Trial Model for Evaluating	
	Putative New Antidepressants	62
	Advancing the Current Clinical Trials Procedure:	
	An Alternative Model	64
	The Component-Specific Clinical Trial	66
	The Component: Specific Clinical Trial	
	and Methods of Measuring Components	
	of the Depressive Disorder	67
	Conclusions	70
	References	71
9	Elaboration of the New Theory of Depression and Conclusions	73
	On the Concept of Depression	77
	Rethinking Depression: The New Conflictual	
	Neurobehavioral States Hypothesis	77
	References	79

**PostScript: The Proposed New Concept of Depression
and the Methodology Recommended for its
Measurement in Future Studies in Clinical Psychopharmacology 81**

Appendix 1: The Multivantaged Assessment Methods 83

Appendix 2: The Video Interview Behavior Evaluation Scales 85

Index. 89

Depression and Drugs

The Neurobehavioral Structure of a Psychological Storm

Katz, M.M.

2013, XVII, 92 p. 8 illus., Softcover

ISBN: 978-3-319-00388-7